5/1
11:25 am
biib
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
4/30
01:59 pm
biib
Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]
Low
Report
Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings [Seeking Alpha]
4/30
12:52 pm
biib
Biogen: Don't Overthink This One [Seeking Alpha]
Low
Report
Biogen: Don't Overthink This One [Seeking Alpha]
4/29
01:03 pm
biib
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $270.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $270.00 price target on the stock.
4/29
09:14 am
biib
Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) [Seeking Alpha]
Medium
Report
Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade) [Seeking Alpha]
4/26
10:58 am
biib
C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer's Disease and Brain Research Market [Yahoo! Finance]
Low
Report
C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer's Disease and Brain Research Market [Yahoo! Finance]
4/25
04:08 pm
biib
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® [Yahoo! Finance]
Medium
Report
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® [Yahoo! Finance]
4/25
02:25 pm
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $215.00 to $200.00. They now have an "equal weight" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $215.00 to $200.00. They now have an "equal weight" rating on the stock.
4/25
11:13 am
biib
Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year [Yahoo! Finance]
Low
Report
Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year [Yahoo! Finance]
4/25
09:06 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Wedbush from $213.00 to $215.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Wedbush from $213.00 to $215.00. They now have a "neutral" rating on the stock.
4/25
08:01 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $325.00 to $300.00. They now have a "buy" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $325.00 to $300.00. They now have a "buy" rating on the stock.
4/24
02:25 pm
biib
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake [Yahoo! Finance]
Low
Report
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake [Yahoo! Finance]
4/24
11:23 am
biib
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
Low
Report
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]
4/24
08:39 am
biib
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $294.00 price target on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $294.00 price target on the stock.
4/23
12:30 am
biib
Should You Be Confident in Biogen (BIIB)? [Yahoo! Finance]
Low
Report
Should You Be Confident in Biogen (BIIB)? [Yahoo! Finance]
4/19
11:01 am
biib
What's in Store for Biogen (BIIB) This Earnings Season? [Yahoo! Finance]
Low
Report
What's in Store for Biogen (BIIB) This Earnings Season? [Yahoo! Finance]
4/19
11:01 am
biib
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]
4/19
10:57 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $290.00 to $270.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $290.00 to $270.00. They now have an "outperform" rating on the stock.
4/18
11:38 am
biib
Alzheimer's Therapeutics Market Size Expected to Surpass USD 8.18 Bn by 2032 [Yahoo! Finance]
Low
Report
Alzheimer's Therapeutics Market Size Expected to Surpass USD 8.18 Bn by 2032 [Yahoo! Finance]
4/18
08:04 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $250.00 to $214.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $250.00 to $214.00. They now have a "neutral" rating on the stock.
4/12
09:12 am
biib
Global Pulmonary Fibrosis Biomarkers Market Size To Exceed USD 6.1 Billion By 2033 | CAGR of 4.3% [Yahoo! Finance]
Medium
Report
Global Pulmonary Fibrosis Biomarkers Market Size To Exceed USD 6.1 Billion By 2033 | CAGR of 4.3% [Yahoo! Finance]
4/12
08:25 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Bank of America Co. from $280.00 to $260.00. They now have a "neutral" rating on the stock.
Medium
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Bank of America Co. from $280.00 to $260.00. They now have a "neutral" rating on the stock.
4/11
09:01 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at JPMorgan Chase & Co. from $270.00 to $240.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at JPMorgan Chase & Co. from $270.00 to $240.00. They now have a "neutral" rating on the stock.
4/10
06:54 am
biib
Global Immunomodulator Market Valuation Set to Total a Staggering US$ 178 Billion by 2034, Spurred by Spike in Chronic Disease Prevalence [Yahoo! Finance]
Low
Report
Global Immunomodulator Market Valuation Set to Total a Staggering US$ 178 Billion by 2034, Spurred by Spike in Chronic Disease Prevalence [Yahoo! Finance]
4/4
10:09 am
biib
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $230.00 to $215.00. They now have an "equal weight" rating on the stock.
Low
Report
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Barclays PLC from $230.00 to $215.00. They now have an "equal weight" rating on the stock.